Integrated genomic characterization of endometrial carcinoma

Gad Getz, Stacey Gabriel, Kristian Cibulskis, Eric S. Lander, Andrey Sivachenko, Carrie Sougnez, Robert Lawrence, Cyriac Kandoth, David J. Dooling, Robert S. Fulton, Lucinda Fulton, Joelle Kalicki-Veizer, Michael D. McLellan, Michelle D. O’Laughlin, Heather K. Schmidt, Richard K. Wilson, Kai Ye, Li Ding, Elaine R. Mardis, Adrian Ally, Miruna Balasundaram, İnanç Birol, Yaron S.n. Butterfield, Rebecca Carlsen, Candace Carter, Andy Chu, Eric Chuah, Hye-Jung E. Chun, Noreen Dhalla, Ranabir Guin, Carrie Hirst, Robert A. Holt, Steven J.m. Jones, Darlene Lee, Haiyan I. Li, Marco A. Marra, Michael Mayo, Richard A. Moore, Andrew J. Mungall, Patrick Plettner, Jacqueline E. Schein, Payal Sipahimalani, Angela Tam, Richard Varhol, A. Gordon Robertson, Andrew D. Cherniack, Itai Pashtan, Gordon Saksena, Robert C. Onofrio, Steven E. Schumacher, Barbara Tabak, Scott L. Carter, Bryan Hernandez, Jeff Gentry, Helga B. Salvesen, Kristin Ardlie, Wendy Winckler, Rameen Beroukhim, Matthew Meyerson, Angela Hadjipanayis, Semin Lee, Harshad S. Mahadeshwar, Peter J. Park, Alexei Protopopov, Xiaojia Ren, Sahil Seth, Xingzhi Song, Jiabin Tang, Ruibin Xi, Lixing Yang, Dong Zeng, Raju Kucherlapati, Lynda Chin, Jianhua Zhang, J. Todd Auman, Saianand Balu, Tom Bodenheimer, Elizabeth Buda, D. Neil Hayes, Alan P. Hoyle, Joshua M. Stuart, Corbin D. Jones, Shaowu Meng, Piotr A. Mieczkowski, Lisle E. Mose, Joel S. Parker, Charles M. Perou, Jeffrey Roach, Yan Shi, Janae V. Simons, Mathew G. Soloway, Donghui Tan, Michael D. Topal, Stephen C. Waring, Junyuan Wu, Katherine A. Hoadley, Stephen B. Baylin, Arnoud Boot, Phillip H. Lai, Timothy J. TricheCarolina 2013 · DOI

Abstract

We performed an integrated genomic, transcriptomic and proteomic characterization of 373 endometrial carcinomas using array-and sequencing-based technologies. Uterine serous tumours and ~25% of high-grade endometrioid tumours had extensive copy number alterations, few DNA methylation changes, low oestrogen receptor/progesterone receptor levels, and frequent TP53 mutations. Most endometrioid tumours had few copy number alterations or TP53 mutations, but frequent mutations in PTEN, CTNNB1, PIK3CA, ARID1A and KRAS and novel mutations in the SWI/SNF chromatin remodelling complex gene ARID5B. A subset of endometrioid tumours that we identified had a markedly increased transversion mutation frequency and newly identified hotspot mutations in POLE. Our results classified endometrial cancers into four categories: POLE ultramutated, microsatellite instability hypermutated, copy-number low, and copy-number high. Uterine serous carcinomas share genomic features with ovarian serous and basal-like breast carcinomas. We demonstrated that the genomic features of endometrial carcinomas permit a reclassification that may affect post-surgical adjuvant treatment for women with aggressive tumours.

Introduction

Endometrial cancer is the most common gynecologic malignancy in the United States. Traditionally, clinical management has relied on a binary classification system: Type I (endometrioid, often estrogen-linked with favorable outcomes) and Type II (serous, more aggressive). However, this histology-based approach is often subjective, particularly for high-grade tumors, leading to low inter-pathologist agreement and potential clinical mismanagement. The Cancer Genome Atlas (TCGA) Research Network sought to resolve these ambiguities through a comprehensive multi-omic characterization of 373 endometrial carcinomas.

Methodology

The researchers employed a multi-platform approach to analyze the cohort, integrating data from:

  • Exome Sequencing: To identify somatic point mutations.
  • SNP Arrays: To detect Somatic Copy Number Alterations (SCNAs).
  • RNA & miRNA Sequencing: To profile the transcriptome and regulatory small RNAs.
  • DNA Methylation Arrays: To assess epigenetic silencing, specifically of the MLH1 promoter.
  • Reverse Phase Protein Arrays (RPPA): To measure the expression levels of 171 key proteins.

To synthesize these diverse datasets, the team utilized unsupervised hierarchical clustering and a novel integration algorithm called SuperCluster to identify robust molecular subgroups.

A New Molecular Classification

The study successfully reclassified endometrial cancer into four distinct molecular groups that transcend traditional microscopic analysis:

  1. POLE Ultramutated: Defined by mutations in the POLE proofreading gene, these tumors exhibit the highest mutation rates recorded in human cancer ($232 \times 10^{-6}$ mutations/Mb) but, paradoxically, have the best clinical prognosis.
  2. MSI Hypermutated: Characterized by Microsatellite Instability and high mutation rates, frequently driven by MLH1 promoter methylation. This group also revealed novel mutations in the chromatin remodeling gene ARID5B.
  3. Copy-Number Low: Primarily composed of endometrioid tumors with frequent CTNNB1 (WNT pathway) mutations and relatively few genomic rearrangements.
  4. Copy-Number High ("Serous-like"): Defined by extensive genomic rearrangements and a high frequency of TP53 mutations (90%).

Key Findings and Clinical Implications

One of the most significant discoveries was that approximately 25% of high-grade endometrioid tumors—traditionally categorized as Type I—actually belong to the "Copy-number high" molecular group. These tumors are molecularly nearly identical to aggressive serous carcinomas, suggesting they are currently being misclassified and potentially undertreated.

Furthermore, the study identified a "cross-cancer convergence." Uterine serous carcinomas share more genomic features with high-grade serous ovarian cancer and basal-like breast cancers than with other uterine subtypes. This suggests that these aggressive malignancies may share a common biological lineage and could respond to similar targeted therapeutic strategies.

From a therapeutic perspective, 93% of endometrioid tumors were found to have mutations in the PI3K/AKT pathway, highlighting a massive opportunity for the use of targeted inhibitors in this patient population.

Conclusion

By integrating genomic, transcriptomic, and proteomic data, this study provides a rigorous, data-driven framework for endometrial cancer classification. This molecular taxonomy offers a more accurate prediction of patient outcomes than traditional histology and identifies specific subgroups that may benefit from targeted therapies or adjusted adjuvant treatment protocols. While prospective clinical trials are necessary to confirm these findings, this work represents a major step toward personalized medicine in gynecologic oncology.

Summary updated

Abstract

We performed an integrated genomic, transcriptomic and proteomic characterization of 373 endometrial carcinomas using array-and sequencing-based technologies. Uterine serous tumours and ∼25% of high-grade endometrioid tumours had extensive copy number alterations, few DNA methylation changes, low oestrogen receptor/progesterone receptor levels, and frequent TP53 mutations. Most endometrioid tumours had few copy number alterations or TP53 mutations, but frequent mutations in PTEN, CTNNB1, PIK3CA, ARID1A and KRAS and novel mutations in the SWI/SNF chromatin remodelling complex gene ARID5B. A subset of endometrioid tumours that we identified had a markedly increased transversion mutation frequency and newly identified hotspot mutations in POLE. Our results classified endometrial cancers into four categories: POLE ultramutated, microsatellite instability hypermutated, copy-number low, and copy-number high. Uterine serous carcinomas share genomic features with ovarian serous and basal-like breast carcinomas. We demonstrated that the genomic features of endometrial carcinomas permit a reclassification that may affect post-surgical adjuvant treatment for women with aggressive tumours. © 2013 Macmillan Publishers Limited. All rights reserved.
BibTeX
@inproceedings{getz2013integrated,
  author = {Gad Getz and Stacey Gabriel and Kristian Cibulskis and Eric S. Lander and Andrey Sivachenko and Carrie Sougnez and Robert Lawrence and Cyriac Kandoth and David J. Dooling and Robert S. Fulton and Lucinda Fulton and Joelle Kalicki-Veizer and Michael D. McLellan and Michelle D. O’Laughlin and Heather K. Schmidt and Richard K. Wilson and Kai Ye and Li Ding and Elaine R. Mardis and Adrian Ally and Miruna Balasundaram and İnanç Birol and Yaron S.N. Butterfield and Rebecca Carlsen and Candace Carter and Andy Chu and Eric Chuah and Hye-Jung E. Chun and Noreen Dhalla and Ranabir Guin and Carrie Hirst and Robert A. Holt and Steven J.M. Jones and Darlene Lee and Haiyan I. Li and Marco A. Marra and Michael Mayo and Richard A. Moore and Andrew J. Mungall and Patrick Plettner and Jacqueline E. Schein and Payal Sipahimalani and Angela Tam and Richard Varhol and A. Gordon Robertson and Andrew D. Cherniack and Itai Pashtan and Gordon Saksena and Robert C. Onofrio and Steven E. Schumacher and Barbara Tabak and Scott L. Carter and Bryan Hernandez and Jeff Gentry and Helga B. Salvesen and Kristin Ardlie and Wendy Winckler and Rameen Beroukhim and Matthew Meyerson and Angela Hadjipanayis and Semin Lee and Harshad S. Mahadeshwar and Peter J. Park and Alexei Protopopov and Xiaojia Ren and Sahil Seth and Xingzhi Song and Jiabin Tang and Ruibin Xi and Lixing Yang and Dong Zeng and Raju Kucherlapati and Lynda Chin and Jianhua Zhang and J. Todd Auman and Saianand Balu and Tom Bodenheimer and Elizabeth Buda and D. Neil Hayes and Alan P. Hoyle and Joshua M. Stuart and Corbin D. Jones and Shaowu Meng and Piotr A. Mieczkowski and Lisle E. Mose and Joel S. Parker and Charles M. Perou and Jeffrey Roach and Yan Shi and Janae V. Simons and Mathew G. Soloway and Donghui Tan and Michael D. Topal and Stephen C. Waring and Junyuan Wu and Katherine A. Hoadley and Stephen B. Baylin and Arnoud Boot and Phillip H. Lai and Timothy J. Triche},
  title = {{Integrated genomic characterization of endometrial carcinoma}},
  booktitle = {Carolina},
  year = {2013},
  doi = {10.1038/nature12113},
}
Figure